Table 1.
Patient and tumor characteristics for endometrial carcinomas with immunohistochemical loss of MLH1, stratified by presence or absence of MLH1 promoter methylation
| MLH1 Immunohistochemical Loss | |||
|---|---|---|---|
| Methylated MLH1 n (%) | Unmethylated MLH1 n (%) | P - value | |
|
Patient Characteristics
| |||
| Age | |||
| Median age at diagnosis | 57 | 52 | 0.4295 |
| Age range | 31-92 | 42-79 | |
| Median Body Mass Index | 32.9 | 30.9 | > 0.999 |
| <30 | 13 (33.3) | 5 (35.7) | |
| ≥ 30 | 26 (66.7) | 9(64.3) | |
| Family History of EC1 | 4 (10.5) | 3 (21.4) | 0.370 |
| Family History of CRC2 | 7 (18.4) | 3 (21.4) | 0.999 |
| Diabetes | 4 (10) | 6 (42.9) | 0.013 |
| Hypertension | 23 (57.5) | 6 (42.9) | 0.371 |
|
Tumor Characteristics | |||
| Histology | |||
| Endometrioid | 35 (87.5) | 11(78.6) | 0.413 |
| Non-Endometrioid | 5 (12.5) | 3(21.4) | |
| FIGO Stage3 | |||
| I & II | 27 (67.5) | 11 (78.6) | 0.515 |
| III & IV | 13 (32.5) | 3 (21.4) | |
| Endometrioid Tumor Grade | |||
| 1 or 2 | 26 (74.3) | 9 (81.8) | |
| 3 | 9 (25.7) | 2 (18.1) | > 0.999 |
| Median depth of myometrial invasion (mm)4 | 9.0 | 9.5 | 0.487 |
| < 50% myometrial invasion | 25 (62.5) | 4 (28.5) | 0.035 |
| ≥ 50% myometrial invasion | 15 (37.5) | 10 (71.4) | |
| Lymphatic/vascular space invasion | 24 (60.0) | 8 (57.1) | > 0.999 |
| Tumor location | |||
| Corpus | 37 (92.5) | 11 (78.6) | 0.173 |
| Lower uterine segment | 3 (7.5) | 3 (21.4) | |
| Tumor Size | |||
| < 4 cm | 21 (52.5) | 8 (57.1) | > 0.999 |
| ≥ 4 cm | 19 (47.5) | 6 (42.9) | |
1
EC, endometrial cancer
2
CRC, colorectal cancer
3
FIGO stage I and II denote endometrial carcinomas confined to the uterus. FIGO stages III and IV represent extra-uterine spread of tumor.
4
Depth of myometrial invasion ≥ 50% total myometrial thickness is associated with increased risk of lymph node metastasis.